15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Peoples Fin, 0 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $56.00 to $56.00, so the covering firms are broadly aligned. The average target of $56.00 sits 22% below the current $71.80. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.72 next quarter toward $7.30 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Hold
Strong Buy00%
Buy00%
Hold1100%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Peoples Fin.
As of Jul, 0 of 1 firms rate PFIS a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PFIS EPS & revenue forecast
EPS · NEXT QUARTER
$1.72
Range $1.63 – $1.80 · 2 analysts · +14% YoY
Next period, 2 analysts expect Peoples Fin to earn $1.72 a share (range $1.63 – $1.80), versus $1.51 a year earlier. Full-year consensus is $6.54, growing to $7.30 the year after.
REVENUE · NEXT QUARTER
$53.5M
Range $53.3M – $53.8M · 2 analysts · +15% YoY
Revenue is expected to reach $53.5M (range $53.3M – $53.8M), +14.7% year-over-year. Full-year consensus is $209.4M, rising to $222.4M next year.
Top analysts covering Peoples Fin
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PFIS.
#1
MB
Matt Breese
Stephens & Co.
Hold
$56.00-22.0% to target
Coverage
—
+ Follow
#2
MB
Matthew Breese
Stephens
Hold
$56.00-22.0% to target
Coverage
—
+ Follow
PFIS stock forecast FAQ
What is PFIS's average 12-month price target?+
The 1 analysts with a live target average $56.00 for Peoples Fin over the next 12 months, ranging from a $56.00 high to a $56.00 low.
Is PFIS stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 1 analyst ratings, 0 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover PFIS?+
1 analysts have an active rating on Peoples Fin, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering PFIS?+
Among analysts who currently cover PFIS, Matt Breese of Stephens & Co. has the strongest overall Quantellect track record. Their current call is Hold with a $56.00 target.
What is Peoples Fin's projected EPS for next quarter?+
The consensus estimate is $1.72 per share (range $1.63 – $1.80) across 2 analysts. Full-year EPS is projected at $6.54, rising to $7.30 the following year.
How much revenue is Peoples Fin expected to report next quarter?+
Consensus revenue is $53.5M (range $53.3M – $53.8M). Full-year revenue is projected at $209.4M, growing to $222.4M next year.
Have analysts been upgrading or downgrading PFIS lately?+
As of Jul, 0 of 1 firms rate PFIS a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PFIS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
